David Baker obtained a BSc Hons degree in Zoology from the University of London, UK, in 1983 and a PhD in Immunology/Pathology at the Hunterian Institute, Royal College of Surgeons of England, London, UK, in 1987. At the latter institute, he began research related to multiple sclerosis and the development of animal models to study translational neuroscience. He moved to University College London (UCL), UK, in 1994 prior to moving to the UCL Queen Square Institute of Neurology in 2000, where he worked on preclinical studies in rodent models of multiple sclerosis with Prof. Gavin Giovannoni. He obtained a personal Chair in 2004. In 2006, he moved to Queen Mary University of London, UK, with Prof. Giovannoni and runs the preclinical model research with the BartsMS group. Although Prof. Baker’s interests have varied over time, his focus has been on the control of neuroimmunological disease and its translational relevance to multiple sclerosis. He has published over 200 peer-reviewed papers. His early career focussed on genetics, T-cell biology, neuroimmunology and the blood–brain barrier. His group uncovered the first experimental evidence for the symptomatic benefit of cannabis and led to the discovery of novel therapeutic agents that have moved from invention to trials in humans. He has recently been examining B cells and their relationship to disease activity in multiple sclerosis.
EM-72357 - Date of preparation: September 2021